Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s disease

20 Dec 2024

Abstract excerpt

Leucine-rich repeat kinase 2 (LRRK2) inhibition is a promising disease-modifying therapy for LRRK2-associated Parkinson's disease (L2PD) and idiopathic PD. However, pharmacodynamic readouts and progression biomarkers for clinical trials aiming for disease modification are insufficient, given that no endogenous marker reflecting enhanced kinase activity of the most common LRRK2 G2019S mutation has yet been...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular transport and secretion
Share to Lysosomal Storage Disorders Research
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39705401
DOI: 10.1093/brain/awae404

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’s diseasePMID 39705401Read ↗

In-depth mass-spectrometry reveals phospho-RAB12 as a blood biomarker of G2019S LRRK2-driven Parkinson’sSemantic proximity Read ↗

Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.Semantic proximity Read ↗

Phospho-signalling deregulation of the mTOR pathway in fibroblasts from LRRK2 Parkinson’s patientsSemantic proximity Read ↗

R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils.Semantic proximity Read ↗

Single molecule array measures of LRRK2 kinase activity in serum link Parkinson’s disease severity to peripheral inflammationSemantic proximity Read ↗

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 CohortsSemantic proximity Read ↗

Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sitesSemantic proximity Read ↗

Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohortsSemantic proximity Read ↗

Accurate MS-based Rab10 phosphorylation stoichiometry determination as readout for LRRK2 activity in Parkinson’s diseaseSemantic proximity Read ↗

Development of a multiplexed targeted mass spectrometry assay for LRRK2-phosphorylated Rabs and Ser910/Ser935 biomarker sites.Semantic proximity Read ↗

Proteome wide association studies of LRRK2 variants identify novel causal and druggable proteins for Parkinson’s diseaseSemantic proximity Read ↗

Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.